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1. Introduction 
The delicate balance between excitation and inhibition within the central nervous system is 
critical to the maintenance of normal brain function. Players key to this balance are 
neurotransmitter transporters. Neurotransmitter transporters are drawn from two families 
of solute carriers (SLC), SLC1 and SLC6. The transporters for glutamate and small neutral 
amino acids belong to the SLC1 family, while transport of monoamines (5-
hydroxytryptamine, dopamine, noradrenaline) and amino acid neurotransmitters (γ-
aminobutyric acid, glycine) are mediated by members of the SLC6 family. These integral 
membrane proteins regulate the concentration of neurotransmitters, such as glutamate and 
glycine, within the synapse. They utilise pre-existing electrochemical gradients to drive the 
transport of neurotransmitters across neuronal and glial membranes, terminating 
neurotransmission and replenishing intracellular levels of neurotransmitter for future 
release. Neurotransmitter transporters are targeted by a number of substances, both 
therapeutic (antidepressants, anticonvulsant, antipsychotics, analgesics, anxiolytics) and 
addictive (cocaine, methampetamine). Their dysfunction is associated with multiple 
disorders, including epilepsy, ischaemic stroke, neuropathic pain and schizophrenia (Dohi 
et al., 2009; Sur & Kinney, 2004). Thus, structure activity studies of transporters are essential 
to provide new insights into their function and direct the design of novel, transporter-
specific therapeutics.  
Since the cloning of the GABA transporter, GAT1, in 1990 (Guastella et al., 1990), directed 
mutagenesis studies have underpinned our understanding of the secondary structure and 
function of neurotransmitter transporters. This work has subsequently been supported, and 
significantly advanced, by the high resolution crystal structures of prokaryotic homologues 
of the SLC1 and SLC6 families. The crystal structure of the SLC1 homologue from Pyrococcus 
horikoshii (GltPh) was the first to be solved at 3.5 Å resolution (Fig 1A) (Yernool et al., 2004). 
This was followed in 2005 by the crystal structure of a homologue of the SLC6 family from 
Aquifex aeolicus (LeuTAa) at 1.65 Å resolution (Yamashita et al., 2005) (Fig 3A). These crystal 
structures have provided important insights into the interactions of transporters with 
substrates, ions, lipids and inhibitors, allowing the postulation of numerous functional 
mechanisms. However, the details provided by these high-resolution structures are 
insufficient to fully understand transport mechanisms. The knowledge obtained from 
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crystal structures and 3D models can be used to direct mutagenesis work (utilising chimeric 
transporters and site-directed mutagenesis), electrophysiology and uptake studies to 
determine the molecular basis for transporter function. The techniques described in this 
chapter can be applied to other membrane proteins, such as G-protein coupled receptors 
and ligand-gated ion channels. 
1.1 The SLC1 family of transporters 
The SLC1 family of neurotransmitter transporters includes five human excitatory amino 
acid transporters (EAAT1 to EAAT5) (Slotboom et al., 1999) and two neutral amino acid 
transporters (ASCT1 and ASCT2) (Arriza et al., 1993; Kanai & Hediger, 2004). The EAATs 
exhibit 40-44% sequence identity with ASCTs and approximately 36% sequence identity 
with the related Na+-coupled aspartate transporter, GltPh (Fig. 2).  The high resolution 
crystal structure of GltPh reveals that SLC1 transporters exist as bowl-shaped trimers (Fig. 
1A) (Yernool et al., 2004). Each protomer is comprised of eight transmembrane domains 
(TM1-8) and two re-entrant hairpin loops (HP1 and HP2). TM1, TM2, TM4, and TM5 
mediate intersubunit contacts and support the ”transport” domain, which is composed of 
TM3, TM6, TM7, TM8, HP1 and HP2 (Fig. 1B). This transport domain mediates substrate 
and ion translocation, and each protomer has an independent translocation pathway. 
The EAATs are critical components of excitatory synapses, where they mediate the high 
affinity uptake of the dominant excitatory neurotransmitter, glutamate, as well as L- and D-
aspartate. Both EAAT1 and EAAT2 are expressed in glia. Of these two subtypes, EAAT2 is 
the more widely distributed and is the major regulator of glutamate concentrations in the 
central nervous system. EAAT3 is expressed on neuronal membranes throughout the brain, 
while EAAT4 is selectively expressed on cerebellar Purkinje cells. EAAT5 is expressed on 
retinal neurons. Glutamate uptake is coupled to the co-transport of three Na+ ions and one 
H+ and the counter-transport of one K+ ion, rendering them electrogenic (Zerangue & 
Kavanaugh, 1996). In addition, glutamate transport is associated with a thermodynamically 
uncoupled Cl- conductance (Fig. 1C) (Fairman et al., 1995, Wadiche et al., 1995). 
1.2 The SLC6 family of transporters 
Members of the SLC6 transporter family are responsible for the transport of monoamine 
(dopamine, serotonin/5-hydroxytryptamine, noradrenaline) and amino acid (GABA and 
glycine) neurotransmitters across cell membranes. Two glycine transporters (GLYT1 and 
GLYT2) have been cloned, and five GLYT1 splice variants (GLYT1a to GLYT1e) and three 
GlyT2 splice variants (GLYT2a to GLYT2c) have been identified. The crystal structure of the 
prokaryotic transporter LeuTAa serves as a useful template for unravelling the functional 
implications of transporter structures (FIG. 3). Members of the SLC6 family are traditionally 
thought to exist as monomers (Horiuchi et al., 2001; Lopez-Corcuera et al., 1993), although more 
recent work suggests that they may form dimers in vivo (Bartholomaus et al., 2008). Each 
subunit is formed by twelve transmembrane domains (TM1-12), with amino- and carboxy-
termini located on the intracellular side of the membrane. Each subunit exhibits a two-fold axis 
of symmetry, with TM1 to TM5 corresponding to TM6 to TM10 with an inverted topology 
repeat. TM1 to TM10 form the core of the transporter, with TM1 and TM6 exhibiting the highest 
degree of sequence homology. They run antiparallel and exist with a central unwound section. 
The area surrounding this central unwound section is critical for substrate and ion binding.    
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Fig. 1. The crystal structure of the prokaryotic transporter GltPh and the stoichiometry of 
transport by the excitatory amino acid transporters (EAAT1- EAAT5) and GltPh. A. GltPh is a 
bowl shaped trimer viewed in the plane of the membrane. Individual protomers are 
coloured red, green and blue. B. A single protomer of the GltPh trimer (PDB 2NWX). The C-
terminal domain is shown in colour; HP1 (yellow), TM7 (orange), HP2 (red) and TM8 
(magenta). Bound aspartate is shown in stick representation and two Na+ ions are shown as 
blue spheres. R276 (HP1) and M395 (TM8), which are discussed in section 3.5, are also 
shown in stick representation. Structures were viewed and rendered in PyMOL 
(http://www.pymol.org) (Schrodinger, 2010). C. Glutamate or aspartate transport via the 
EAATs is coupled to three Na+ ions and one H+, followed by the counter-transport of one K+ 
ion. Binding of Na+ and substrate to the EAATs activates a thermodynamically uncoupled 
Cl- conductance (pink arrow). D. Aspartate transport via GltPh is coupled to the co-transport 
of three Na+ ions, but is not coupled to the movement of either H+ or K+ ions. Na+ and 
aspartate binding to GltPh also activates an uncoupled Cl- conductance (pink arrow). 
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TM 1
EAAT1 M T K S N G E E P K M G G R M E R F Q Q G V R K R T L L A K K K V Q N I T K E D V K S Y L F R N A F V L L T V T A V I V G T I L G F T L R P Y R . M S Y R E V K Y F S F P G E
EAAT2 M A S T E G A N N M P K Q V E V R M H D S H L S S E E P K H R N L GM R M C D K L G K N L L L S L T V F G V I L G A V C G G L L R L A A P I H P D V V M L I A F P G D
EAAT3 M G K P T S S G C D W R R F L R N H W L L L S T V A A V V L G I V V G V L V R G H S E L S N L D K F Y F A F P G E
ASCT1 M E K S N E T N G Y L D S A Q A G P A A G P G A P G T A A G R A R R C A G F L R R Q A L V L L T V S G V L A G A G L G A A L R G L S . L S R T Q V T Y L A F P G E
Gltph M G L Y R K Y I E Y P V L Q K I L I G L I L G A I V G L I L G H Y G . Y A D A V K T Y V K P F G D
TM 2 T M 3
EAAT1 L L M R M L QM L V L P L I I S S L V T GM A A L . D S K A S G K M GM R A V V Y Y M T T T I I A V V I G I I I V I I I H P G K G T K E N M H . . . . . . . R E G K I V R V T
EAAT2 I L M R M L K M L I L P L I I S S L I T G L S G L . D A K A S G R L G T R A M V Y Y M S T T I I A A V L G V I L V L A I H P G N P K L K K Q L G . . . . . . P G K K N D E V S
EAAT3 I L M R M L K L V I M P L I I S S M I T G V A A L . D S N V S G K I G L C A V V Y Y F S T T V I A V I L G I V L V V S I K P G V T Q K V N E I N . . . . . . R T G K T P E V S
ASCT1 M L L R M L R M I I L P L V V C S L V S G A A S L . D A S C L G R L G G I A V A Y F G L T T L S A S A L A V A L A F I I K P G S G A Q T L Q S S D L G L E D S G P P P V P K E
Gltph L F V R L L K M L V M P I V F A S L V V G A A S I S P A R . L G R V G V K I V V Y Y L L T S A F A V T L G I I M A R L F N P G A G I H L A V G G . . . . . . . . . Q Q F Q P K
T M 4 a TM 4 b TM 4 c
EAAT1 A A D A F L D L I R N M F P P N L V E A C F K Q F K T N Y E K R S F K V P I Q A N E T L V G A V I N N V S E A M E T L T R I T E E L V P V P G S V N G V N A L G L V V F S M C
EAAT2 S L D A F L D L I R N L F P E N L V Q A C F Q Q I Q T V T K K V L V A P P S E E A N T T K A V I S L L N E T M N E A P E E T K I V I K K G L E F K D GM N V L G L I G F F I A
EAAT3 T V D A M L D L I R N M F P E N L V Q A C F Q Q Y K T K R E E V K P A S D P G G N Q T E V S V T T A M T T M S E N K T K E Y K I V G L Y S D G I . . . . N V L G L I I F C L V
ASCT1 T V D S F L D L A R N L F P S N L V V A A F R T Y A T D Y K V V T Q N S S S G N V T H E K I P I G T E I E GM . . . . . . . . . . . . . . . . . . . . . N I L G L V L F A L V
Gltph Q A P P L V K I L L D I V P T N P F G A L A N G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Q V L P T I F F A I I
c T M 6
EAAT1 F G F V I G N M K . . . . . . . . E Q G Q A L R E F F D S L N E A I M R L V A V I M W Y A P V G I L F L I A G K I V E M E D M G V I G G Q L A M Y T V T V I V G L L I H A V I
EAAT2 F G I A M G K M G . . . . . . . . E Q A K L M V E F F N I L N E I V M K L V I M I M W Y S P L G I A C L I C G K I I A I K D L E V V A R Q L GM Y M I T V I V G L I I H G G I
EAAT3 F G L V I G K M G . . . . . . . . E K G Q I L V D F F N A L S D A T M K I V Q I I M C Y M P I G I L F L I A G K I I E V E D W E I F R K L G L Y M A T V L S G L A I H S L V
ASCT1 L G V A L K K L G . . . . . . . . S E G E D L I R F F N S L N E A T M V L V S W I M W Y V P V G I M F L V G S K I V E M K D I I V L V T S L G K Y I F A S I L G H V I H G G I
Gltph L G I A I T Y L M N S E N E K V R K S A E T L L D A I N G L A E A M Y K I V N G V M Q Y A P I G V F A L I A Y V M A E Q G V K V V G E L A K V T A A V Y V G L T L Q I L L
HP1a HP1b TM 7a T M 7b
EAAT1 V L P L L Y F L V T R K N P W V F I G G L L Q A L I T A L G T S S S S A T L P I T F K C L E E N N G V D K R V T R F V L P V G A T I N M D G T A L Y E A L A A I F I A Q V N N
EAAT2 F L P L I Y F V V T R K N P F S F F A G I F Q A W I T A L G T A S S A G T L P V T F R C L E D N L G I D K R V T R F V L P V G A T I N M D G T A L Y E A V A A I F I A QM N G
EAAT3 V L P L I Y F I V V R K N P F R F A L GM A Q A L L T A L M I S S S S A T L P V T F R C A E E K N H V D K R I T R F V L P V G A T I N M D G T A L Y E A V A A V F I A Q V N G
ASCT1 V L P L I Y F V F T R K N P F R F L L G L L A P F A T A F A T C S S S A T L P S M M K C I E E N N G V D K R I S R F I L P I G A T V N M D G A A I F Q C V A A V F I A Q L N N
Gltph V Y F V L L K I Y G I D P I S F I K K A K D A M L T A F V T R S S S G T L P V T M R V A K E M G I S E G I Y S F T L P L G A T I N M D G T A L Y Q G V C T F F I A N A L G
HP2 a HP2 b TM 8
EAAT1 F E L N F G Q I I T I S I T A T A A S I G A A G I P Q A G L V T M V I V L T S V G L P T D D . . . . . . I T L I I A V D W F L D R L R T T T N V L G D S L G A G I V E H L S R
EAAT2 V I L D G G Q I V T V S L T A T L A S I G A A S I P S A G L V T M L L I L T A V G L P T E D . . . . . . I S L L V A V D W L L D R M R T S V N V V G D S F G A G I V Y H L S K
EAAT3 M D L S I G Q I I T I S I T A T A A S I G A A G V P Q A G L V T M V I V L S A V G L P A E D . . . . . . V T L I I A V D W L L D R F R T M V N V L G D A F G T G I V E K L S K
ASCT1 V E L N A G Q I F T I L V T A T A S S V G A A G V P A G G V L T I A I I L E A I G L P T H D . . . . . . L P L I L A V D W I V D R T T T V V N V E G D A L G A G I L H H L N Q
Gltph S H L T V G Q Q L T I V L T A V L A S I G T A G V P G A G A I M L A M V L E S V G L P L T D P N V A A A Y A M I L G I D A I L D M G R T M V N V T G D L T G T A I V A K T E G
EAAT1 H E L K N R D V E M G N S V I E E N E M K K P Y Q L I A Q D N E T E K P I D S E T
EAAT2 S E L D T I D S Q H R M H E D I E M T K T Q S V Y D D T K N H R E S N S N Q C V Y A A
EAAT3 K E L E Q V D V S S E V N I V N P F A L E P T I L D N E D S D T K K S Y V N G G F S V D K S D T I S F T Q T S Q F
ASCT1 K A T K K G E Q E L A E V K V E A I P N C K S E E E T S P L V T H Q N P A G P V A S A P E L E S K E S V L
Gltph
T M 5
 
 
 
 
 
 
 
Fig. 2. Amino acid sequence alignment of SLC1 family members. Sequences for EAAT1-3,  
ASCT1 and GltPh are shown. Transmembrane domains are indicated using the colour 
scheme as for the structure of GltPh in Fig. 1. Homologous regions are highlighted in black. 
Residues highlighted in red boxes with yellow background are discussed in the text. The 
blue line (connecting Q93 to V452 in EAAT1) indicates that cysteine mutants of these two 
residues can be cross-linked (see section 3.4 for details). 
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Fig. 3. The crystal structure of the prokaryotic transporter LeuTAa and the stoichiometry of 
transport by the GLYTs and LeuTAa. A. The structure of LeuTAa viewed in the plane of the 
membrane (PDB 2A65). Bound leucine is shown in A space-filling representation, and the 2 
Na+ ions are shown as purple spheres. Extracellular loop 2 (EL2, grey) and extracellular loop 
4 (EL4, blue) are highlighted (see section 2.2 for details). EL4 residues R531 and K532 
(orange stick representation) and I545 (red stick representation) are also highlighted (see 
section 3.2 for discussion). B. Bound leucine interacts with transmembrane domains TM1 
and TM6. The hydrogen bond between the nitrogen atom of leucine and the side chain of 
serine 265 is represented by a dashed line (see section 3.2 for details). Na+ ions are shown as 
purple spheres. C. Glycine transport via the GLYTs is coupled to two (GLYT1) or three 
(GLYT2) Na+ ions and one Cl- ion. D. Alanine transport via LeuTAa is coupled to the co-
transport of two Na+ ions. 
Mammalian members of the SLC6 family share 20-25% sequence identity with the 
prokaryotic transporter LeuTAa (FIG. 4). GLYT1 and GLYT2 are structurally similar and 
exhibit 48% sequence homology (FIG. 4), but they display significant functional differences. 
GLYT1 is predominantly expressed in glia at excitatory glutamatergic synapses, where they 
are responsible for regulating glycine, which acts as a co-agonist at NMDA receptors. Of the 
five GLYT1 isomers identified, GLYT1b and GLYT1c are nervous system-specific. In 
contrast, GLYT2 is typically localized with glycine receptors at inhibitory glycinergic 
synapses (spinal cord). The translocation of glycine by both transporters is coupled to the 
co-transport of Na+ and Cl- (FIG. 3), but the stoichiometry of ion-flux coupling by GLYT1 
and GLYT2 differs. The transport of one glycine molecule is coupled to the co-transport of 
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two Na+ ions and one Cl- ion for GLYT1 transporters, while the movement of three Na+ ions 
and one Cl- ion is coupled to glycine transport for GLYT2 (Fig. 3C).  
GLYT2 M D C S A P K E M N K L P A N S P E A A A A Q G H P D G P C A P R T S P E Q E L P A A A A P P P P R V P R S A S T G A Q T F Q S A D A R A C E A E R P G V G S C K L S S P R
GLYT1 - - - - - - - - - - - - - - - - - - M A A A H G - - - - P V A P - S S P E Q - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
LeuTAa - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
GLYT2 A Q A A S A A L R D L R E A Q G A Q A S P P P G S S G P G N A L H C K I P F L R G P E G D A N V S V G K G T L E R N N T P V V GW V N M S Q S T V V L A T D G I T S V L P G
GLYT1 - - - - - - - - V T L L P V Q R S F F L P P F S G A T P S T S L - - - - - - - - - - - A E S V L K V W H G A Y N S G L L P Q L - - - - M A Q H S L A M A Q N - - - - - - - G
LeuTAa - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
GLYT2 S V A T V A T Q E D E Q G D E N K A R G N W S S K L D F I L S M V G Y A V G L G N V W R F P Y L A F Q N G G G A F L I P Y L M M L A L A G L P I F F L E V S L G Q F A S Q G
GLYT1 A V P S E A T K R D Q - - - - N L K R G N W G N Q I E F V L T S V G Y A V G L G N V W R F P Y L C Y R N G G G A F M F P Y F I M L I F C G I P L F F M E L S F G Q F A S Q G
LeuTAa - - - - - - - - - - - - - - M E V K R E H W A T R L G L I L A M A G N A V G L G N F L R F P V Q A A E N G G G A F M I P Y I I A F L L V G I P L M W I E W A M G R Y G G A Q
GLYT2 P V S V W K A - - - - - - - I P A L Q G C G I A M L I I S V L I A I Y Y N V I I C Y T L F Y L F A S F V S V L P W G S C N N P W N T P E C K D K T K L L L D S C V I S D H P
GLYT1 C L G V W R I - - - - - - - S P M F K G V G Y GM M V V S T Y I G I Y Y N V V I C I A F Y Y F F S S M T H V L P W A Y C N N P W N T H D C A G - - - - V L D A S N L T N G S
LeuTAa G H G T T P A I F Y L L W R N R F A K I L G V F G L W I P L V V A I Y Y V Y I E S W T L G F A I K F L V G L V P E P P P N A T - - - - - - - - - - - - - - - - - - - - - - -
GLYT2 K I Q I K N S T F C M T A Y P N V T M V N F T S Q A N K T F - - V S G S E E Y F K Y F V L K I S A G - - I E Y P G - E I R W P L A L C L F L A W V I V Y A S L A K G I K T S
GLYT1 R - - - - - - - - - - - - - P A A L P S N L S H L L N H S L Q R T S P S E E Y W R L Y V L K L S D D - - I G N F G - E V R L P L L G C L G V S W L V V F L C L I R G V K S S
LeuTAa - - - - - - - - - - - - - - - - - - - - - - - - - - - D P D S I L R P F K E F L Y S Y I G V P K G D E P I L K P S L F A Y I V F L I T M F I N V S I L I R G I S K G I E R F
TM 6 a TM 6 b
GLYT2 G K V V Y F T A T F P Y V V L V I L L I R G V T L P G - A G A G I W Y F I T P K W E K L T D A T V W K D A A T Q I F F S L S A A W G G L I T L S S Y N K F H N N C Y R D T L
GLYT1 G K V V Y F T A T F P Y V V L T I L F V R G V T L E G - A F D G I M Y Y L T P QW D K I L E A K V W G D A A S Q I F Y S L G C A W G G L I T M A S Y N K F H N N C Y R D S V
LeuTAa A K I A M P T L F I L A V F L V I R V F L L E T P N G T A A D G L N F L W T P D F E K L K D P G V W I A A V G Q I F F T L S L G F G A I I T Y A S Y V R K D Q D I V L S G
GLYT2 I V T C T N S A T S I F A G F V I F S V I G F M A N E R K V N I E N V A D Q G P G I A F V V Y P E A L T R L P L S P F W A I I F F L M L L T L G L D T M F A T I E T I V T S
GLYT1 I I S I T N C A T S V Y A G F V I F S I L G F M A N H L G V D V S R V A D H G P G L A F V A Y P E A L T L L P I S P L W S L L F F F M L I L L G L G T Q F C L L E T L V T A
LeuTAa T A A T L N E K A E V I L G G S I S I P A A V A F F G V A N A V A I A K A G A F N L G F I T L P A I F S Q T A G G T F L G F L W F F L L F F A G L T S S I A I M Q P M I A F
GLYT2 I S D E F P - K Y L R T H K P V F T L G C C I C F F I M G F P M I T Q G G I Y M F Q L V D T Y A A S Y A L V I I A I F E L V G I S Y V Y G L Q R F C E D I E M M I G F Q P N
GLYT1 I V D E V G N E W I L Q K K T Y V T L G V A V A G F L L G I P L T S Q A G I Y W L L L M D N Y A A S F S L V V I S C I M C V A I M Y I Y G H R N Y F Q D I QM M L G F P P P
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Fig. 4. Amino acid sequence alignment of GLYT1, GLYT2 and LeuTAa. Transmembrane 
domains are indicated using the colour scheme used for the structure of LeuTAa. 
Homologous regions are highlighted in black. Chimeric transporters were generated 
between GLYT1 and GLYT2 in which extracellular loops 2 and 4 (highlighted with yellow 
edges) were switched between the two transporters (see section 2.2 for details). Residues 
highlighted in red boxes with yellow background are discussed in the text. 
2. The use of chimeras in studies of neurotransmitter transporters 
Chimeras provide an excellent tool for the study of neurotransmitter transporters. Switching 
specific regions/structures between transporters can provide insights into transporter 
function and substrate selectivity and inform the design of directed mutagenesis studies. 
Further, chimeras between mammalian and bacterial transporters have the potential to 
assist with the crystallisation of transporters, thereby facilitating the determination of the 
structure of mammalian transporters. We employ a fusion PCR technique to create chimeric 
junctions at specific amino acid locations, allowing for the precise design of chimeras. We 
have produced numerous chimeras using this method, including chimeras of GLYT1 and 
GLYT2. 
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2.1 PCR fusion methodology 
Conventional chimera construction methodology relies on restriction enzyme cloning, in 
which unique restriction enzyme sites are introduced into both the acceptor and the donor 
proteins. While this technique allows for the production of chimeras with specific/known 
junction points, the availability of unique restriction enzyme sites can impose limitations on 
the design of potential chimeras. In contrast, the PCR fusion technique (Shevchuk et al., 
2004) creates chimeric junctions at any amino acid, without the need for restriction enzyme 
sites. In this method (Fig. 5), each segment of the final chimera is amplified in individual 
PCR reactions. The primers are designed to engineer complementary overlapping sequences 
onto the junction-forming ends of each product. The PCR primers possess typical properties 
(18-24 nucleotides in length and a melting temperature of ~64ºC). The overlapping 
sequences correspond to the desired chimeric junction sites between subunits. The strands 
of the PCR products (duplex DNAs) are routinely separated and allowed to reanneal by 
cycles of heating and cooling. A partially duplex chimera can form as a result of annealing 
by the complementary regions of different fragments, one half of the chimeras will have free 
3’-ends that can be elongated by DNA polymerase. The other half will have free 5’-ends that 
cannot be elongated. If more than two PCR products are involved, eventually a full-length 
chimera forms. The resulting duplex chimera is then amplified by PCR with oligonucleotide 
primers containing restriction enzyme sites at the 5’ and 3’ ends of the DNA of the chimera 
to facilitate subcloning into a suitable vector. For chimeras that require more than three 
fragments, it is often best to produce an initial chimera of three fragments and then 
incorporate additional fragments as required. It is important to obtain complete DNA 
sequences of any clones generated in this manner to confirm the junction sites and also to 
ensure that there have been no spurious sequence changes. 
2.2 Identifying determinants of drug selectivity 
Drugs that have selective effects in vivo are much sought after. Such compounds potentially 
have minimal side effects, making them attractive options as therapeutics. Studies suggest 
that the GLYTs may provide a novel therapeutic target for the development of drugs to treat 
neurological disorders and pain. In particular, GLYT1 is considered a potential target for the 
development of agents to treat schizophrenia (Sur et al., 2004). GLYT2 is a key target for 
studies to develop molecules to treat chronic pain (Aragon & Lopez-Corcuera, 2003). N-
Arachidonylglycine (NAGly) is an endogenous derivative of arachidonic acid. NAGly has 
been shown to induce analgesia in rat models of neuropathic and inflammatory pain (Succar 
et al., 2007; Vuong et al., 2008). One of the mechanisms of action of NAGly is the inhibition 
of GLYT2 (IC30 = 3 μM), whilst it has no effect on GLYT1 (Wiles et al., 2006). Understanding 
the molecular basis of NAGly selectivity may aid in the development of novel analgesic 
compounds. 
Extracellular loops EL2 and EL4 have been implicated in mediating inhibition of the GLYTs. 
Residues that contribute to the binding site of Zn2+, a non-competitive inhibitor of GLYT1, 
have been identified in EL2 and EL4 (Ju et al., 2004). Zn2+ has been proposed to inhibit 
GLYT1 by binding to EL2 and EL4, restricting the movement of these loops and thus 
preventing glycine transport. LeuTAa, the bacterial homologue of the GLYTs, has been 
crystallized in the presence of clomipramine, a non-competitive inhibitor (Singh et al., 2007), 
and tryptophan, a competitive inhibitor (Singh et al., 2008). Clomipramine was shown to  
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Fig. 5. A schematic summary of the construction of chimera GLYT1(EL2) using the PCR 
fusion methodology. The DNA sequence of the donor cDNA (GLYT1) is in blue and the 
acceptor cDNA (GLYT2) is in red. cDNAs of GLYT1 and GLYT2 in the presence of their 
corresponding primers (I and II, III and IV, V and VI) undergo PCR to generate three 
fragments with the appropriate homologous ends. The fragments are ‘fused’ together in 
another reaction, in which the single strands from the overlapping regions serve as internal 
primers (see text). The final PCR amplification reaction fuses (‘zips’) all the fragments in the 
presence of primers I and VI, which, in this case, include restriction site for the enzymes 
KpnI and XbaI.  The final product is the chimera GLYT1(EL2) with two unique restriction 
sites engineered on either end to allow for insertion of the chimeric gene into the vector 
pOTV. The restriction sites may be altered for subcloning into different vectors.    
stabilize LeuTAa in an occluded state by interacting with a number of transmembrane 
domains and displacing the tip of EL4. In contrast, the presence of the competitive inhibitor 
tryptophan appeared to trap the transporter in an open-to-out conformation. Four separate 
tryptophan molecules were identified in this crystal structure, with one of them found to be 
interacting with EL2 and EL4. These observations suggest that these loops play key roles in 
the inhibition of GLYTs.  
In order to ascertain the molecular basis for the inhibitory activity of NAGly on GLYT2, 
chimeras were generated between GLYT1 and GLYT2, in which EL2 and/or EL4 were 
switched (Fig. 6). A chimera is named according to its parental transporter, with the inserted 
loop in parentheses. For example, GLYT2(EL2) is predominantly GLYT2 with the EL2 of 
GLYT1. One of the important controls required when using a chimeric protein to 
understand structure-function relationships is the ability to maintain the functional 
properties of the chimera. For chimeras that are predominantly GLYT2, the EC50 for glycine 
3 separate PCR 
reactions generate 
fragments to be 
Final PCR amplification fuses all fragments 
KpnI 
KpnI I 
II 
III 
IV 
V 
VI 
I
VI 
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Tm 65°  Tm 65°  
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XbaI 
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was very similar to that of the parental GLYT2 transporter, which indicates that these 
chimeras transport glycine similar to GLYT2. With the GLYT1-based chimeras, GLYT1(EL2) 
and GLYT1(EL2, EL4), the EC50 for glycine was increased by 6-8 fold compared to GLYT1. 
Thus, for the GLYT1-based chimeras, the transport of glycine differs slightly from the parent 
transporter; and, therefore, we are not able to be as confident that other functional changes 
are solely due to the region of interest. Nevertheless, the experiments using the GLYT2-
based chimeras yielded valuable information concerning the domains responsible for 
NAGly sensitivity. GLYT2 is inhibited by NAGly, whereas GLYT2(EL2) and GLYT2(EL4) 
have reduced sensitivity (Edington et al., 2009). These observations suggest that EL2 and 
EL4 contribute to forming an inhibitory site on GLYT2.  
EL4
EL2
GLYT2 GLYT2(EL2) GLYT2(EL2)
GLYT1 GLYT1(EL2) GLYT1(EL4)  
Fig. 6. A schematic diagram of the topology of the wild-type transporters GLYT2 and 
GLYT1 and their EL2 and EL4 chimeras. Black indicates the regions of the transporter from 
GLYT2 and white indicates the regions from GLYT1. Shown are GLYT2, GLYT2(EL2), 
GLYT2(EL4), GLYT1, GLYT1(EL2), and GLYT1(EL4). 
3. Site-directed mutagenesis 
Identifying domains that are responsible for conferring functional differences between 
transporters is only the first step in understanding the molecular processes that dictate 
neurotransmitter transporter function. Chimeric and directed mutagenesis studies are 
mutually beneficial and, when used in conjunction, can increase the efficiency and efficacy 
of experimentation. Information obtained in the study of chimeric transporters helps to 
focus site-directed mutagenesis studies to specific domains. The introduction of point 
mutations within these regions can then provide very useful information about the function 
of specific residues and the location of substrate and ion binding sites. Conventional 
mutagenesis studies utilise amino acid sequence alignments between multiple members of a 
transporter family to direct and design mutagenesis studies. However, this work often relies 
on the mutation knocking out a particular function and thereby assigning that function to 
the residue of interest. This approach can generate misleading conclusions because loss of 
function can be the result of a number of changes, many of which do not necessarily reflect a 
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direct disruption of the interaction being investigated. To avoid this issue, we employ 
knowledge obtained from recent advances in high resolution transporter crystal structures 
and homology models to improve our accuracy in predicting residues of interest and 
successfully creating functional mutants. Crystal structures provide a powerful 3-
dimensional tool that enables us to visualise each residue and their individual contacts with 
the substrate/ions/other residues, thus improving the selection process. In addition, 
homology models provide a computational prediction of the global effect of a mutation. 
Thus, they can be used to predict which mutations will be accommodated by individual 
transporters. We have undertaken numerous mutagenesis studies that have, among other 
things, identified the glycine substrate binding site in GLYT1 and GLYT2, helped to 
characterise selective drug-binding sites on the GLYTs and clarified the specificity of ion 
and substrate interactions with the EAATs and GltPh.  
3.1 Directed mutagenesis methodology 
Site-directed mutagenesis is a powerful tool that makes select changes to the genetic code of 
a protein to alter the amino acid sequence. The resultant mutant protein exhibits subtle 
structural changes. The ability to selectively manipulate amino acids in a controlled manner 
provides a powerful tool that is exploited by researchers undertaking structure-function 
studies. It should be noted that the importance of loss of function mutants must be 
interpreted with caution. Disruption of transport functions following a mutation can result 
in loss of function. However, loss of function could also result from misfolding of a protein 
or altered expression levels. Therefore, mutants that lose function are only useful if the 
cause of loss of function can be accurately ascertained. 
Site-directed mutagenesis involves the use of specifically designed primers (sense and 
antisense) that include a point mutation of interest in the centre of the sequence. Each 
primer is 18-24 nucleotides in length with a melting temperature of ~64°C. The primers 
incorporate the mutation into an intronless gene, using the cDNA as template in a PCR 
reaction, with the elongation by DNA polymerase. Following amplification, the 
endonuclease DpnI, which recognizes methylated and hemimethylated DNA, can be added 
to the amplification reaction to digest the parental cDNA. It is important to obtain DNA 
sequences to confirm the mutation. The mutant DNA is subcloned into the appropriate 
vector. In the studies we describe, the Oocyte Transcription Vector (pOTV) is used, as it 
enables efficient RNA production and facilitates high expression levels of protein in Xenopus 
laevis oocytes. To construct a double point mutation, one set of primers may be used when 
the two residues are next to each other or in close proximity. However, if the two mutations 
are further apart, DNA encoding one mutation is initially made and used as the template for 
the second mutation. Site-directed mutagenesis kits are sold by many companies (e.g., 
Stratagene, Promega, Clonetech). We routinely use the QUIKCHANGE(tm) Site-Directed 
Mutagenesis kit from Stratagene. 
3.2 Mutagenesis to identify determinants of drug selectivity of glycine transporters 
The use of chimeric GLYT transporters allowed the identification of EL2 and EL4 as being 
regions critical for determining the selective activity of NAGly on GLYT2 (Edington et al., 
2009). Having identified the regions of interest, we used site-directed mutagenesis to 
identify the residues within these regions that form the selective drug-binding site. Our 
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chimeric study (see Section 2.2) revealed that NAGly interacted with EL4, so the aim of the 
subsequent mutagenesis study was to identify the key residues in EL4 that play a role in 
determining the differential sensitivity of GLYT2 compared to GLYT1.  
The EL4 of GLYT2 exhibits 60% sequence identity with the GLYT1 EL4. Point mutations 
were introduced at all positions within the GLYT2 EL4 that differed from GLYT1. In total, 
eleven mutations were produced. Each resulted in a functional mutant GLYT2 transporter 
that exhibited glycine transport unchanged from that of the wild-type transporter. Three 
mutations resulted in changes in sensitivity to NAGly. Mutation of arginine at position 531 
to leucine (R531L) and lysine at position 532 to glycine (K532G) resulted in modest 
reductions in NAGly sensitivity (IC30 = 13 ± 2 µM and 9 ± 1 µM, respectively) compared to 
GLYT2 (IC30 = 3.4 ± 0.6 µM). In contrast, the mutation of isoleucine at position 545 to leucine 
(I545L) markedly reduced NAGly sensitivity (IC30>30µM) (Edington et al., 2009). 
This work revealed that three residues within EL4 are critical to the inhibitory activity of 
NAGly on GLYT2. Modelling studies place I545 in the middle of EL4, while R531 and K532 
are located at the edge of EL4. It is surprising that a conservative mutation at position 545 
(an isoleucine to a leucine) would have the most dramatic impact. Two likely possibilities 
follow. (1) NAGly may bind to I545, and the I545L mutation may distort the way that 
NAGly fits into the binding site. (2) The I545L mutation may alter the conformation of the 
two arms of EL4, which then impacts on the way that this domain interacts with other 
elements that may be crucial for NAGly binding. The carboxyl groups of NAGly may 
interact with the positively charged R531 and K532 residues. Further structural studies are 
required to fully characterize the specific interaction sites between the NAGly and GLYT2. 
3.3 Substrate selectivity of the GLYTs  
GLYT1 and GLYT2 can be differentiated by their substrate selectivity and inhibitor 
sensitivity. GLYT1 transports both glycine and the N-methyl derivative of glycine, 
sarcosine, while GLYT2 only transports glycine (Supplisson & Bergman, 1997). In addition, 
GLYT1 is selectively inhibited by N[3-(4-fluorophenyl)-3-(4'-phenylphenoxy) 
propylsarcosine (NFPS) (Aubrey & Vandenberg, 2001). The crystal structure of LeuTAa 
provides a good working model for the study of GLYTs. As with the GLYTs, the substrate 
binding site of LeuTAa is formed at the junction between TM1–5 and TM6–10. It is composed 
of amino acid residues from TM1 and TM6 (Yamashita et al., 2005). Both of these 
transmembrane domains contain an unwound segment, and many of the substrate contact 
sites are with the main chain atoms of these unwound segments. Sequence alignments 
between LeuTAa and the GLYTs revealed that there are a number of identical residues and 
some key differences in the predicted substrate binding site. In particular, in the crystal 
structure of LeuTAa, the amino group of leucine is hydrogen-bonded to the hydroxyl group 
of the side chain of serine at position 256 (Fig 3B). This residue is located in TM6. We 
focused on the role of the corresponding residues in GLYT1b and GLYT2a to investigate if 
this residue is a determinant of GLYT substrate selectivity (Vandenberg et al., 2007). 
Serine at position 256 in LeuTAa corresponds to a glycine residue (G305) in GLYT1b and a 
serine residue (S481) in GlyT2a. The G305 in GLYT1b was mutated to a serine (GLYT1-
G305S) and S481 in GLYT2a was mutated to a glycine (GLYT2-S481G) using site directed 
mutagenesis (Vandenberg et al., 2007). In contrast to wild type GLYT2a, sarcosine is a 
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substrate of the GLYT2a-S481G mutant. The maximal current (97 ± 2%) and EC50 (26.2 ± 1.3 
μM) of sarcosine at the mutant receptor are similar to that for wild-type GLYT1b (87 ± 1%, 
22 ± 1 μM). The introduction of the corresponding mutation, G305S, into GLYT1b reduced 
levels of surface expression to approximately 10% of wild type. To overcome this limitation, 
two additional mutants were generated, GLYT1b-G305A and GLYT2a-S481A. Glycine 
transport of both mutant receptors is similar to that of wild type. However, incorporation of 
the S481A substitution into GLYT2a produced a transporter that could transport sarcosine 
with an efficacy similar to that of GLYT1b (70 ± 3%), but with a reduced affinity (590 ± 50 
μM) relative to wild type. Combined, these findings demonstrate that residues at this 
position are important for sarcosine transport. For GLYT2a, sarcosine can be transported if 
an alanine or a glycine residue is present at this site, but not if a serine residue is present. 
3.4 Mutagenesis to identify transport and channel domains of glutamate transporters 
Glutamate transporters have two distinct functions: ion coupled glutamate transport and 
glutamate-activated chloride channel activity. In 1995, two studies demonstrated that the 
two functions co-exist in the same protein (Fairman et al., 1995; Wadiche et al., 1995). 
Glutamate binding is required for activation of the channel, but the direction of Cl- ion flow 
through the channel domain is uncoupled from the direction of glutamate transport. This 
raised the question as to how the protein could support the dual functions. In the following 
section, we will describe how mutagenesis has been used to understand the structural basis 
for the dual functions of glutamate transporters. This is an interesting example of the 
complementary nature of mutagenesis and crystallography approaches to understand the 
functional properties of this class of transporters.  
Prior to the determination of the crystal structure of GltPh, mutagenesis was used to identify 
residues that may play a role in transporter function. Valine 452 (V452) of EAAT1 is located 
in the HP2 domain, and the V452C mutation does not alter the functional properties of the 
transporter. After modification of the V452C mutant with the methanethiosulfonate (MTS) 
reagent, [2-(trimethylammonium)ethyl] methanethiosulfonate (MTSET), the protein is no 
longer capable of transporting glutamate; but it still retains the glutamate-activated chloride 
channel (Ryan & Vandenberg, 2002). This suggests that the two functions are mediated by 
distinct conformational states of the transporter. In a separate study, our group attempted to 
identify regions of the transporter that form the chloride channel. We focussed our 
mutagenesis studies on TM2. TM2 contains a number of positively charged residues at the 
extracellular edge of the helix and a number of uncharged serine and threonine residues in 
the middle of the helix. We postulated that positive charges at the extracellular edge would 
attract anions into the channel and the hydrophilic residues within the channel would 
facilitate anion movement through the channel. To address this hypothesis, we mutated the 
positively charged residues at the extracellular edge to cysteine residues and probed the 
reactivity of the cysteine residues to both positively and negatively charged MTS reagents. 
The negatively charged MTS reagents had faster rates of reactivity than the positively 
charged MTS reagents, which suggested that the positively charged residues do attract 
negative charges to the extracellular edge of TM2.  Substitutions of the hydrophilic serine 
and threonine residues in the middle of TM2 to small aliphatic residues significantly altered 
the anion permeability of the channel without affecting the transport function. This 
confirmed that the two functional properties of the transporter are mediated by separate 
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domains and also that the serine and threonine residues are likely to line the pore of the 
channel.  
The studies described above were carried out prior to any knowledge of the three 
dimensional structure of the transporter, and so we attempted to identify how close the 
channel domain was from various other sites on the transporter by cross-linking 
experiments. Cysteine residues were introduced within TM2 and then at various other sites 
of the transporter, including V452 (see above). A disulfide bond formed spontaneously 
between V452C (in HP2) and Q93C (in TM2), indicating that these two residues must come 
into close proximity. From this study a crude structural model for these parts of the 
transporter was developed (Fig. 7A).  
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Fig. 7. Structural predictions of the relationship between the glutamate binding and 
translocation domain and the chloride conducting domain.  A. A structural model for 
glutamate transport and Cl- ion permeation of EAAT1. We have omitted the K+ ion and H+ 
for simplicity. The thick line is in the plane of the paper and the dashed line is behind the 
plane of the paper. V452C can form a disulfide bond with Q93C. We propose that Cl- ions 
interact with residues along TM2. In this model, we suggest that glutamate and Na+ ions 
permeate the same pore as Cl- ions, but that there are separate molecular determinants for 
the two functions. B, C. The structure of the transport domain composed of HP1 (yellow), 
TM7 (orange), HP2 (red) and TM8 (purple) relative to TM2, which contains molecular 
determinants for Cl- permeation. Bound aspartate is shown in space-filling representation, 
and two Na+ ions are represented as blue spheres. The residues equivalent to Q93 and V452 
are in stick representation and coloured black. B. Shows the distance between Q93 and V452 
in the occluded state (PDB 2NWX), while C is the Hg2+ cross-linked structure showing the 
conformational changes required to bring Q93 and V452 into close proximity  (PDB 3KBC, 
Hg2+ shown as a yellow sphere).   
The crystal structure of GltPh was published in late 2004 (see above for a description of the 
structure); and, whilst the structure revealed many important details about substrate 
binding, the nature of the mechanism of activation of the chloride channel was not clear. The 
equivalent residues to V452 and Q93 in GltPh are approximately 20 Ǻ apart (Fig. 7B, 
equivalent residues in a GltPh protomer are represented in black), which suggested that 
these residues were unlikely to come sufficiently close to form a disulfide bond. The first 
step in resolving this apparent contradiction came from confirming that hydrophilic 
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residues in TM2 of GltPh also form part of the lining of the chloride channel lumen, as 
observed for EAAT1 (Ryan & Mindell, 2007). The laboratory of Olga Boudker then repeated 
the crosslinking experiments in GltPh, using cysteine mutants and adopting a similar 
approach to the one our group had done for EAAT1. Whilst spontaneous disulfide bonds 
did not form between the two residues in GltPh, it was possible to catalyse the formation of a 
bond between the two cysteine residues using Hg2+. It was concluded that the two domains 
can indeed move sufficiently to allow the two residues to come into close proximity. The 
cross-linked GltPh was also crystallized, and its structure was compared with the original 
structure (Fig. 7C). This study identified the conformational changes required to bring about 
the formation of the crosslinks and also suggested a mechanism for the transport process 
and how this process can lead to channel activation (Reyes et al., 2009). Briefly, the three 
transport domains (consisting of TM3, TM6, TM7 and TM8 and HP1 and HP2 from each 
protomer) move as three separate units through a rigid trimerization scaffold. TM2 is part of 
the scaffold, whilst HP2 is part of the transport domain. It would appear that the sliding 
movement of the transport domain relative to the rigid trimerization scaffold allows 
chloride ions to pass through the gap between the two functional domains (Vandenberg et 
al., 2008). Further mutagenesis will be required to verify this proposal. This series of 
experiments starting with mutagenesis, followed by crystallography, further mutagenesis 
and then further crystallography, which will also be followed up by further mutagenesis, 
highlights how the two approaches to understanding structure and function relationships 
can complement one another and provoke new ideas and concepts in protein function. 
3.5 Substrate affinity and K
+
 ion coupling in EAAT1  
For the last section of this chapter, we will focus on an example of how mutagenesis 
approaches have been used to understand substrate and ion binding properties of the 
glutamate transporter family. Many of the residues that have been implicated in substrate 
and ion binding/translocation (Bendahan et al., 2000; Kavanaugh et al., 1997; Vandenberg et 
al., 1995) and chloride permeation (Ryan et al., 2004) are conserved throughout the 
glutamate transporter family. In particular, the carboxy-termini of both the EAATs and GltPh 
are highly conserved and contain the substrate and Na+ binding sites. Despite their 
significant amino acid identity, the EAATs and GltPh display several functional differences. 
The EAATs transport aspartate and glutamate with similar affinity, while GltPh is selective 
for aspartate over glutamate. In addition, GltPh transport is not coupled to the co-transport 
of H+ or the counter-transport of K+ (Boudker et al., 2007; Ryan et al., 2009). Examination of 
the amino acid sequences of the substrate binding site of the EAATs and GltPh does not 
reveal any residues that can clearly account for the differences observed in substrate 
selectivity or affinity. However, an arginine residue is in close proximity to the substrate 
binding site of both the EAATs and GltPh, but it is located in TM8 in the EAATs and in HP1 
of GltPh (Fig 1B). The aim of our study was to investigate the functional effect of the location 
of a positively charged arginine residue in two members of the glutamate transporter 
family, EAAT1 and GltPh. 
In order to examine the role of this arginine residue, two double mutant transporters were 
produced. In EAAT1 the arginine residue was moved from TM8 to HP1 
(EAAT1S363R/R477M), and the reverse double mutation was introduced into the gene for 
GltPh (GltPhR276S/M395R). Switching the arginine residue from TM8 to HP1 in EAAT1 had 
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no effect on substrate selectivity, but it did increase affinity for both glutamate and aspartate 
and abolished K+ coupling. The apparent affinity for both L-glutamate and L-aspartate was 
increased ~130 fold, and it was similar to the affinity of L-aspartate in GltPh (Ryan et al., 
2009). The counter-transport of one K+ ion per transport cycle is thought to be important for 
the relocation of the EAATs to the outward-facing state. The movement of an arginine 
residue from TM8 to HP1 has potentially slowed the return of the empty transporter to the 
extracellular facing side, thus contributing to the decrease in observed affinity values. In 
contrast, the inverse changes in GltPh (GltPhR276S/M395R) resulted in a functional 
transporter that has a ~4-fold reduction in the affinity for aspartate compared to wild type. 
The substitutions did not affect substrate selectivity or introduce K+ dependence. 
The crystal structure of GltPh reveals that the backbone carbonyl group of the arginine 
residue in HP1 forms a direct contact with the substrate. However, our mutagenesis studies 
suggest that it is the side chain that is influencing transport properties. A possible 
explanation is that the conformation of the HP1 loop region and also the proximal TM8 is 
influenced by the arginine side chain and neighbouring residues. Thus, mutating this 
arginine may influence the conformation of the backbone carbonyl group, which in turn 
may influence substrate affinity. 
The movement of K+ ions through the transporter is likely to rely upon multiple 
conformational changes and interactions. Disruption of any of these interactions via a 
mutation is liable to result in loss of K+ coupling. However, to introduce K+ coupling will 
require multiple mutations. This may explain why the double mutation is sufficient to 
abolish K+ coupling in EAAT1, but not introduce it into GltPh. 
4. Conclusion 
Directed mutagenesis has been particularly useful in understanding the structure and 
function of mammalian membrane proteins. In this chapter we have outlined our approach 
to structure-activity studies of neurotransmitter transporters in the solute carrier (SLC) 
families, SLC1 and SLC6. We have used examples from our work on the excitatory amino 
acid transporters (EAATs), the archaeal aspartate transporter (GltPh), glycine transporters 
(GLYTs) and the prokaryotic leucine transporter (LeuTAa).  
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